Cargando…

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor

We aimed to determine the metabolomic profile of kidney cells under high glucose conditions and following sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Targeted metabolomics using the Absolute IDQ-p180 kit was applied to quantify metabolites in kidney cells stimulated with high glucose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Hyung Ah, Seo, Jong-Hyun, Lee, Sunhwa, Yu, Mi-yeon, Bae, Eunjin, Kim, Dong Ki, Kim, Yon Su, Kim, Da Jung, Yang, Seung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899225/ https://www.ncbi.nlm.nih.gov/pubmed/36739309 http://dx.doi.org/10.1038/s41598-023-28850-3

Ejemplares similares

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
por: Kang, Dong Yoon, et al.
Publicado: (2022)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
por: Seo, Ji A
Publicado: (2019)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
por: Lee, Seung Eun, et al.
Publicado: (2022)

Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis
por: Koh, Eun Sil, et al.
Publicado: (2023)

Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
por: Lee, Seul-Gee, et al.
Publicado: (2020)

Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats
por: Kapoor, Sarika, et al.
Publicado: (2015)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
por: Dekkers, Claire C J, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

Bicarbonate-Independent Sodium Conductance of Na/HCO(3) Cotransporter NBCn1 Decreases NMDA Receptor Function
por: Choi, Inyeong, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim, Yoojin, et al.
Publicado: (2012)

Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition
por: Lee, Ho Gyun, et al.
Publicado: (2023)

The role of local IL6/JAK2/STAT3 signaling in high glucose–induced podocyte hypertrophy
por: Jo, Hyung Ah, et al.
Publicado: (2016)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
por: Choi, Y, et al.
Publicado: (2023)

A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
por: Kume, Shinji, et al.
Publicado: (2022)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
por: Oliveras, Laia, et al.
Publicado: (2023)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
por: Hsieh, Cheng-Yang, et al.
Publicado: (2022)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0n1rordll364q91db4no3ebjjg